A Double-Blind, Placebo-Controlled, Randomized Withdrawal, Multicenter Clinical Trial Evaluating the Efficacy, Safety, and Tolerability of Cariprazine in a Dose-Reduction Paradigm in the Prevention of Relapse in Patients With Schizophrenia
Latest Information Update: 11 Mar 2025
At a glance
- Drugs Cariprazine (Primary)
- Indications Schizophrenia
- Focus Therapeutic Use
- Sponsors AbbVie; Allergan; Forest Laboratories
Most Recent Events
- 11 Mar 2025 According to Mitsubishi Tanabe Pharma Corporation media release, the company has obtained the regulatory approval of cariprazine in Thailand.
- 07 Jul 2021 This trial has been completed in Bulgaria, according to European Clinical Trials Database
- 16 Jun 2021 Status changed from active, no longer recruiting to discontinued ( the study was stopped: FDA Released Allergan from it's post marketing requirement)